{
  "pmcid": "10085918",
  "sha256": "1823b84f4dfbff9da70163fecaa7b89b991c21600b4d39654ef0410fec5d5020",
  "timestamp_utc": "2025-11-09T15:05:00.462756+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.204848484848487,
    "reading_ease": 15.439772727272754,
    "word_count": 264
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "As part of a randomized phase II trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Eligible patients were randomized"
      },
      "Participants": {
        "score": 1,
        "evidence": "Eligible patients were randomized"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized to perioperative systemic therapy (experimental) or CRS–HIPEC alone (control)"
      },
      "Objective": {
        "score": 1,
        "evidence": "the present study compared patient-reported outcomes (PROs)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "PROs were assessed using EORTC QLQ-C30, QLQ-CR29, and EQ-5D-5L questionnaires at baseline, after neoadjuvant treatment (experimental), and at 3 and 6 months postoperatively"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 79 analyzed patients, 37 (47%) received perioperative systemic therapy"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 79 analyzed patients"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "worsening of fatigue [mean difference (MD) + 14, p = 0.001], loss of appetite (MD + 15, p = 0.003), hair loss (MD + 18, p < 0.001), and loss of taste (MD + 27, p < 0.001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "worsening of fatigue [mean difference (MD) + 14, p = 0.001], loss of appetite (MD + 15, p = 0.003), hair loss (MD + 18, p < 0.001), and loss of taste (MD + 27, p < 0.001)"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}